Pharmacological treatment of exertional dyspnoea in stable COPD patients.
Exertional dyspnoea is one of the most common and disabling symptoms in patients with stable chronic obstructive pulmonary disease (COPD). Because little can be done for its resolution, the idea of its symptomatic treatment is attractive. There is no gold standard for the pharmacological management of exertional dyspnoea in stable COPD. A reassessment of the available literature shows the current perspectives and limits.
Melani
A S
AS
Respiratory Pathophysiology Unit, Azienda Ospedaliera Senese, Policlinico Le Scotte, Siena, Italy.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004417:Dyspnea / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000150:complications* / Q000503:physiopathology; D010100:Oxygen / Q000627:therapeutic use*; D005082:Physical Exertion; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D001993:Bronchodilator Agents; D011619:Psychotropic Drugs; D010100:Oxygen